

Parenteral versus Oral Iron Therapy in Children with Iron Deficiency Anemia and the Safety Profile of Parenteral Iron Therapy

Ejaz ur Rehman¹, Mehrozia Nuzhat², Muhammad Saad Raza³, Muhammad Rafique^{4*}, Habibullah Mumtaz⁵, Sana Tariq⁶

ABSTRACT

OBJECTIVE: To assess the differences between parenteral and oral iron supplementation therapy for children with iron-deficient anemia.

METHODOLOGY: This prospective, randomized study was conducted at the Pediatric Healthcare Centre, Karachi, from January to December 2024. Pediatric patients aged 1-15 years diagnosed with anemia were randomly assigned to two groups: group A received oral iron therapy, and group B received parenteral iron therapy during the study period. We used SPSS 23 to analyze the data. Continuous variables were assessed as means and standard deviations, while categorical variables were analyzed as frequencies and percentages.

RESULTS: Total 82 patients were included in the study, mean age was reported as 4.2 ± 1.6 years, the gender distribution was reported as 51(62.1%) male and 31(37.8%) females, Post treatment laboratory investigations indicated retics% of 3.63 ± 1.22 , hemoglobin as 7.48 ± 0.89 , MCV as 68.9 ± 4.8 and serum iron level as 181.5 ± 41.6 in group A oral therapy patients, while retics % of 9.17 ± 2.33 , Hemoglobin as 9.2 ± 1.87 , MCV as 70.2 ± 5.61 and serum iron level as 214.2 ± 70.9 in group B Parenteral therapy group respectively.

CONCLUSION: Parenteral therapy improves iron values more quickly and significantly.

KEYWORDS: Iron deficiency anemia, Iron therapy, Parenteral, pediatric.

INTRODUCTION

One of the most prevalent dietary illnesses among children is iron deficiency anemia (IDA), which is a major cause of morbidity.

Worldwide. About half of all children under the age of five in developing nations like Pakistan are impacted, primarily as a result of socioeconomic inequalities, infections, and poor nutrition¹.

The main course of action for treating childhood IDA is iron supplementation, which can be given orally or parenterally, depending on the severity, tolerance, and adherence to therapy². For children with mild to severe IDA, the World Health Organization advised utilizing oral iron therapy as the first line of treatment³. Iron is administered as ferrous fumarate, ferrous gluconate, or ferrous sulfate in liquid or tablet form. Oral therapy is non-invasive, easy to administer, economical, and does not require medical

professionals to administer the dose⁴. When using oral iron supplements, gastrointestinal problems such as diarrhea, constipation, nausea, upset stomach, and abdominal discomfort are the most often reported side effects⁵. Delayed-release formulations are well recognized as kinder to the gastrointestinal tract, which lowers the likelihood of complications.

On the other hand, giving children iron supplements directly into their bloodstream is thought to be an aggressive approach to treating severe IDA, as waiting for delayed absorption of iron by oral supplementation may lead to negative consequences and serious difficulties. By bypassing the GI tract and delivering iron directly to the bloodstream, this technique eliminates GI-related side effects while quickly and effectively increasing iron levels⁶. Although they are uncommon, complications from parenteral iron therapy can range from injection site infections to severe allergic reactions (such as anaphylaxis). Other non-medical factors related to parenteral iron therapy include the high cost of treatment, the need for a medical professional to administer it, and multiple consultations and visits to a medical facility⁷.

In developing nations like Pakistan, it can be challenging to identify a manageable and appropriate route of administration while keeping in mind the patient's circumstances and socioeconomic status. To understand patterns of health-seeking behavior and barriers to accessing treatment, it is important to assess parental approval, hesitancy toward invasive therapies, financial barriers, and other related factors. The purpose of this study is to give a detailed

¹Assistant Professor, Pediatrics, United Medical and Dental College, Karachi, Pakistan

²Senior Registrar, Pediatrics, Jinnah Medical and Dental College/ Jinnah Medical College Hospital, Karachi, Pakistan

³Assistant Professor, United Medical and Dental College, Karachi, Pakistan

⁴Associate Professor, Dow University of Health Sciences, Karachi, Pakistan

⁵Registrar, United Medical and Dental College, Karachi, Pakistan

⁶Manager Research & Development, Tabba Kidney Institute, Karachi, Pakistan

Correspondence: drmuhammadrafique@yahoo.com

doi: 10.22442/jlumhs.2026.01354

Received: 27-05-2025

Revised: 13-04-2026

Accepted: 19-05-2026

Online First: 22-07-2026



examination of the differences between parenteral and oral iron supplementation therapy for children with iron-deficient anemia.

METHODOLOGY

This prospective, randomized study was conducted at the Pediatric Healthcare Centre, Karachi, from January to December 2024. Prior approval was obtained from the Institutional Review Board, (ERC approval # CBC/HC.PH-II/No.61). The sample size was calculated with the help of the WHO sample size calculator, keeping the total registered number of pediatric patients visited the outpatient department and diagnosed with Anemia in the past 6 months ($n=103$), a confidence interval of 95%, and a margin of error of 5%; the estimated minimum sample size was $n=82$. Pediatric patients aged 1-15 years diagnosed with anemia were allotted to two groups using a computer-generated randomization sequence, with an equal allocation ratio (1:1). Group A received oral iron therapy. In contrast, Group B received parenteral therapy for iron-deficiency anemia during the study period.

Inclusion criteria

- Children aged 1–15 years
- Diagnosed with iron deficiency anemia
- Hb below age-specific cutoff
- Parental consent obtained

Exclusion criteria

- Hemoglobinopathy
- Chronic kidney disease
- Malignancy
- Recent blood transfusion
- Current iron therapy
- Severe systemic illness

Both genders were enrolled in the study. Informed consent was obtained in a language understood by the eligible patients' parents and/or guardians. After signing the consent form, we documented all demographic details and medical history, including previous surgeries, hospital stays, daily activities, infection rates, morbidity, and antenatal diagnosis. We documented laboratory investigations, including Hemoglobin, MCV, and serum iron levels. (Table I)

Table I: Cut-off values of blood components according to age in pediatric population

Age	Hb g/dL	MCV fL	Serum Iron $\mu\text{g/dL}$
New born	<13.2	<100	<63
6-24 months	<11.3	<68-72	<35
2-6 years	<11.5	<75	<22
6-12 years	<12	<77	<39
12-18 years	<13 (M) <12 (F)	<78	

Source: Nathan and Oski's Hematology of Infancy and Childhood, Seventh edition, Elsevier, 2009.

Group A patients were prescribed oral ferrous sulphate (dose 5mg/kg/day) for the duration of 4 weeks. Group B patients were prescribed parenteral intramuscular iron sorbitol (Dose 1.5mg/kg/day) for 4 weeks as well. After 1 week, hemoglobin values were reassessed to document changes, and after 4 weeks, serum iron levels and clinical improvements were reported.

Statistical Package for the Social Sciences (SPSS) version 23 was used to enter, sort, and analyze the data. Normality of data was assessed with the help of the Shapiro-Wilk test; continuous variables were assessed as mean and standard deviation, while categorical variables were analyzed as frequency and percentages.

RESULTS

Total 82 patients were included in the study, mean age was reported as 4.2 ± 1.6 years, the gender distribution was reported as 51(62.1%) male and 31 (37.8%) females, age was categorized as 1-3, 3.1-6, 6.1-9, 9.1-12 and 12.1 – 15 years with patients reported as 12(14.6%), 19(23.1%), 26(31.7%), 19 (23.1%) and 6(7.3%) respectively. (Table II)

Table II:

Demographic variables in study participants

Variables	n (%)
Gender	Male 51(62.1%)
	Female 31(37.8%)
Age (Years)	1 to 3 12(14.6%)
	3.1 to 6 19(23.1%)
	6.1 to 9 26(31.7%)
	9.1 to 12 19(23.1%)
	12.1 to 15 6(7.3%)

Laboratory tests were divided into oral and parenteral groups. Group A patients receiving oral medication at baseline (before therapy initiation) had a serum iron value of 39.8 ± 1.52 , a hemoglobin level of 7.24 ± 1.02 , an MCV of 56.2 ± 6.16 , and a reticulocyte percentage of 0.81 ± 0.34 . At baseline, group B patients receiving parental therapy had a reticulocyte percentage of 1.03 ± 0.13 , hemoglobin of 6.12 ± 0.99 , MCV of 53.2 ± 5.11 , and serum iron of 40.1 ± 0.93 . For retics percentage, HB, MCV, and serum iron, the corresponding p-values were 0.23, 0.89, 0.44, and 0.21.

After treatment, group A oral therapy patients had a reticulocyte percentage of 3.63 ± 1.22 , hemoglobin levels of 7.48 ± 0.89 , MCV of 68.9 ± 4.8 , and serum iron of 181.5 ± 41.6 . Post-treatment hematological parameters improved in both groups; however, parenteral therapy showed significantly greater increases in hemoglobin and serum iron levels than oral therapy (Table III).

Table III: Comparison of laboratory investigations between oral versus parenteral group patients at baseline and post-treatment

Variables		Group A n=41	Group B n=41	P- Value
		Ferrous sulphate	Iron Sorbitol	
Pre treatment	Retics %	0.81±0.34	1.03±0.13	0.234
	HB g/dL	7.24±1.02	6.12±0.99	0.891
	MCV	56.2±6.16	53.2±5.11	0.441
	Serum Iron ug/dL	39.8±1.52	40.1±0.93	0.214
Post treatment	Retics %	3.63±1.22	9.17±2.33	<0.001
	HB g/dL	7.48±0.89	9.2±1.87	<0.001
	MCV	68.9±4.8	70.2±5.61	0.071
	Serum Iron ug/dL	181.5±41.6	214.2±70.9	0.031

The reported complications in oral therapy group were headache 1(1.2%), abdominal pain 13(15.8%), Transient mild hypotension 7(8.5%) and Vasovagal syncope 1(1.2%) respectively, while Parenteral therapy patients reported headache 3(3.6%), abdominal pain 2(2.4%), Transient mild hypotension 9 (10.9%) and Vasovagal syncope 3(3.6%) respectively. The p-values were 0.04, <0.0001, 0.02, and 0.03, respectively. (Table IV)

Table IV: Reported complications of study participants within groups

Variables	Group A	Group B	P-Value
	Ferrous sulphate	Iron Sorbitol	
Headache	1(1.2%)	3(3.6%)	0.04
Abdominal pain	13(15.8%)	2(2.4%)	<0.0001
Transient mild hypotension	7(8.5%)	9(10.9%)	0.02
Vasovagal syncope	1(1.2%)	3(3.6%)	0.03

DISCUSSION

Iron deficiency anemia (IDA) continues to be a major contributor to pediatric morbidity worldwide, even though it is one of the most common nutritional illnesses in children⁸⁻¹⁰. Iron supplements, administered orally or parenterally, are the cornerstone of therapy. The current study compared the efficacy and safety of oral and parenteral iron therapy in children with IDA. The two groups' hematological values at baseline were comparable, indicating that they had a similar level of anemia before therapy. After treatment¹¹⁻¹², both therapeutic strategies led to an increase in hematologic markers like serum iron levels, reticulocyte count, and hemoglobin. In contrast, children treated with parenteral iron showed a larger and faster increase in hemoglobin and iron markers compared to those who were given oral supplements¹³.

Earlier research indicates that parenteral iron therapy leads to a faster replenishment of iron stores¹⁴ because it overcomes gastrointestinal absorption barriers and has superior bioavailability. This trend is consistent with the larger body of research on pediatric IDA. A large pediatric systematic review of 4,010 children revealed that the pooled hemoglobin increase was somewhat in favor of intravenous (IV) iron over oral iron (26.7 vs. 22.1 g/L), with a trend toward quicker correction¹⁵. Similarly, numerous reviews and editorials stress that IV iron is more effective than oral iron, especially when a quick remedy is needed¹⁶⁻¹⁷. In pediatric IV iron groups, Hb typically rises by 3-4 g/dL, with noticeable changes in MCV and ferritin within a few weeks¹⁸. Additionally, several comparative trials and meta-analyses of adults and mixed-age IDA have shown that IV iron therapy yields significantly greater and faster increases in haemoglobin, as well as greater iron reserves, than oral iron therapy¹⁹. Consequently, the superior post-treatment indices seen in the parenteral group are not only plausible but also consistent with the established pattern: parenteral iron bypasses intestinal constraints and adherence concerns, resulting in rapid erythropoiesis (high reticulocytes) and higher Hb, MCV, and serum iron over the same interval as oral therapy¹⁷.

Although both treatments were effective, their safety profiles differed. Gastrointestinal issues, particularly abdominal discomfort, a common adverse consequence of oral supplementation, were more frequently reported by patients who underwent oral iron therapy. In contrast, parenteral treatment was associated with a somewhat higher incidence of vasovagal responses and transient hypotension, probably because injectable therapy is intrusive¹⁸⁻²⁰. With proper clinical monitoring, most adverse effects were minor and manageable, even in light of these 18 occurrences. A targeted pediatric review concludes that, for the most part, modern parenteral iron seems safe and only causes minor, treatable adverse effects. Several pediatric IV iron series (ferric carboxymaltose, iron sucrose, dextran derivatives) report a low incidence of adverse events (about 2–6%), with only a few minor infusion reactions and a low rate of anaphylaxis¹⁷. Compared to oral treatment (3.7% vs 77.9%), IV iron had significantly fewer adverse effects in a retrospective pediatric IDA cohort²¹. A comprehensive systematic review of pediatric IDA compared IV, oral, and transfusion administration and found that IV iron had comparable, or even somewhat reduced, pooled adverse event rates (7.3%) to oral iron (8.4%)²². This positive profile is reflected in meta-analyses of adults and pregnancies, which demonstrate that IV iron raises Hb levels more quickly and is associated with fewer gastrointestinal adverse effects and fewer general adverse events than oral iron. In this way, parenteral iron is well supported as both more effective and acceptably safe, particularly when oral therapy is restricted by adherence,

intolerance, malabsorption, or severity.

These findings of this study, which corroborate existing clinical recommendations^{23,24}, oral iron therapy remains a recommended first-line treatment for mild to moderate pediatric IDA because of its simplicity of use, affordability, and acceptable safety profile²⁵. Parenteral iron therapy may be a helpful choice when anemia must be treated right away or when oral treatment is ineffective or not well tolerated²⁶. Pediatric evaluations and guidance support IV iron when oral treatment is ineffective, intolerable, or too slow for clinical needs. To prevent transfusion or reduce the neurocognitive hazards associated with persistent IDA, rapid replenishment of iron and Hb reserves is necessary²⁷. In these cases, parenteral administration may restore iron reserves and hematological health more quickly²⁸.

This study has several limitations that must be considered when interpreting the results. The findings may not be widely applicable because the study was conducted at a single location with a small sample size. Additionally, the study could not assess the treatment's long-term results or the recurrence of anemia because the follow-up period lasted only four weeks. Future multicenter studies with larger sample sizes and longer follow-up times are recommended to better evaluate the relative efficacy and long-term safety of different iron supplementation regimens in children.

CONCLUSION

By comparing oral and parenteral iron therapy for the treatment of pediatric iron deficiency anemia (IDA), this study contributes to the growing body of knowledge. Although both methods work, parenteral iron raises iron levels more quickly and noticeably. Clinicians should consider the severity of the anemia, the patient's tolerance, and any underlying diseases that can affect iron metabolism or absorption when choosing a therapy plan. The long-term implications of each therapy, including their impact on quality of life and overall cost-effectiveness, require more investigation.

Ethical Permission: CBC Healthcare Centres, Cantonment Board, Karachi IRB approval letter No. CBC/HC.PH-II/No.61.

Conflict of interest: There is no conflict of interest between the authors.

Financial Disclosure / Grant Approval: No funding agency was involved in this research.

Data Sharing Statement: The corresponding author can provide the data supporting the findings of this study's findings upon request. Privacy or ethical restrictions bound us from sharing the data publicly.

AUTHOR CONTRIBUTION

Rehman EU: Objective, consultation, write-up

Nuzhat M: Data collection, consultation

Raza MS: Ethical consideration, data collection

Rafique M: Data entry, data interpretation, final approval

Mumtaz H: Data analysis, ethical consideration

Tariq S: Data Analysis, data entry

REFERENCES

- Juul A, Gravholt CH, De Vos M, Koledova E, Cools M. Individuals with numerical and structural variations of sex chromosomes: interdisciplinary management with focus on fertility potential. *Front Endocrinology*. 2023 May 5; 14: 1160884.
- Ebea Uguanyi PO, Vidyasagar S, Connor JR, Frazer DM, Knutson MD, Collins JF. Oral iron therapy: Current concepts and future prospects for improving efficacy and outcomes. *Br J Haematology*. 2024 Mar; 204(3): 759-73.
- Gill PA, Inniss S, Kumagai T, Rahman FZ, Smith AM. The role of diet and gut microbiota in regulating gastrointestinal and inflammatory disease. *Front Immunology*. 2022 Apr 5; 13: 866059.
- Mantadakis E, Alexiadou S, Zikidou P. Parenteral iron therapy for pediatric patients. *Hematology*. 2024 Jan 19; 5(1): 35-47.
- Rehman T, Agrawal R, Ahamed F, Das S, Mitra S, Kumar D et al. Optimal dose and duration of iron supplementation for treating iron deficiency anaemia in children and adolescents: A systematic review and meta-analysis. *PLoS one*. 2025 Feb 14; 20(2): e0319068.
- Leung AK, Lam JM, Wong AH, Hon KL, Li X. Iron deficiency anemia: an updated review. *Current Pediatr Rev*. 2024 Aug 1; 20(3): 339-56.
- Chaber R, Helwich E, Lauterbach R, Mastalerz-Migas A, Matysiak M, Peregud-Pogorzelski J et al. Diagnosis and Treatment of Iron Deficiency and Iron Deficiency Anemia in Children and Adolescents: Recommendations of the Polish Pediatric Society, the Polish Society of Pediatric Oncology and Hematology, the Polish Society of Neonatology, and the Polish Society of Family Medicine. *Nutrients*. 2024 Oct 25; 16(21): 3623.
- Bathla S, Arora S. Prevalence and approaches to manage iron deficiency anemia (IDA). *Crit Rev Food Sci Nutr*. 2022 Nov 14; 62(32): 8815-28.
- Russo G, Guardabasso V, Romano F, Corti P, Samperi P, Condorelli A et al. Monitoring oral iron therapy in children with iron deficiency anemia: an observational, prospective, multicenter study of AIEOP patients (Associazione Italiana Emato-Oncologia Pediatrica). *Ann Hematol*. 2020 Mar; 99: 413-20.
- Benson AE, Lo JO, Achebe MO, Aslan JS, Auerbach M, Bannow BT et al. Management of iron deficiency in children, adults, and pregnant individuals: evidence-based and expert consensus recommendations. *Lancet Haematology*. 2025 May 1; 12(5): e376-88.
- Abdelhafez AH, Hamdan SM. Advancements in Pediatric Hematology and Oncology. *Sch J App*

- Med Sci. 2024 Dec; 12: 1710-23.
12. Talathi S, Namjoshi S, Raghu V, Wendel D, Oliveira SB, Reed K et al. Evaluation and management of iron deficiency in children undergoing intestinal rehabilitation—a position paper from the NASPGHAN intestinal rehabilitation special interest group. *J Pediatr Gastroenterol Nutr.* 2023 May 1; 76(5): 672-83.
 13. Mattiello V, Schmutge M, Hengartner H, von der Weid N, Renella R, SPOG Pediatric Hematology Working Group. Diagnosis and management of iron deficiency in children with or without anemia: consensus recommendations of the SPOG Pediatric Hematology Working Group. *Eur J Pediatr.* 2020 Apr; 179: 527-45.
 14. Leung AK, Lam JM, Wong AH, Hon KL, Li X. Iron deficiency anemia: an updated review. *Current Pediatr Rev.* 2024 Aug 1; 20(3): 339-56.
 15. Cadieux A, Pham M, Speckert M, Borkhoff C, Parkin P, Hamid J. Interventions to Treat Pediatric Iron Deficiency Anemia: A Systematic Review and Meta-Analysis. *J Pediatrics.* 2025; 114898. <https://doi.org/10.1016/j.jpeds.2025.114898>.
 16. Auerbach M, Adamson J. How we diagnose and treat iron deficiency anemia. *Am J Hematology.* 2016; 91. <https://doi.org/10.1002/ajh.24201>.
 17. Mantadakis E, Alexiadou S, Zikidou P. Parenteral Iron Therapy for Pediatric Patients. *Hematology.* 2024; <https://doi.org/10.3390/hemato5010005>.
 18. Raza M, Usman M, Mahmood M, Malik M, Hanif F. Efficacy Of Intravenous Therapy In Children With Iron Deficiency Anaemia Having Poor Response To Oral Iron Therapy. *J Rawalpindi Med Coll.* 2025; <https://doi.org/10.37939/jrnc.v29i2.2842>.
 19. Zhao C, He W. Efficacy of oral vs. intravenous iron for the treatment of iron deficiency anemia in different conditions: A systematic review and meta-analysis. *Biomedical Reports.* 2025; 24. <https://doi.org/10.3892/br.2025.2084>.
 20. Rehman T, Agrawal R, Ahamed F, Das S, Mitra S, Kumar D et al. Optimal dose and duration of iron supplementation for treating iron deficiency anaemia in children and adolescents: A systematic review and meta-analysis. *PloS One.* 2025 Feb 14; 20(2): e0319068.
 21. Manokaran K, Spaan J, Cataldo G, Lyons C, Mitchell P, Sare T et al. Inpatient management of iron deficiency anemia in pediatric patients with inflammatory bowel disease: A single center experience. *World J Clin Pediatr.* 2024; 13. <https://doi.org/10.5409/wjcp.v13.i1.89318>
 22. Kazanci E, Korkmaz M, Orhaner B. Efficacy and safety of intravenous iron sucrose treatment in children with iron deficiency anemia. *Med Sci Discover.* 2019; <https://doi.org/10.36472/msd.v6i10.317>.
 23. Twomey A, Baumgartner J, Schembri L, Kozłowska WJ, Balfour-Lynn IM. Prevalence and treatment of iron deficiency in children with cystic fibrosis. *J Pediatr Gastroenterol Nutr.* 2026 Feb; 82(2): 566-73.
 24. Qunibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. *Arzneimittelforschung.* 2010 Jun; 60(06): 399-412.
 25. Idamokoro M. Physiological traits, anthropometric characteristics and motor development of rural children in Nkonkobe Municipality, South Africa (Doctoral dissertation, University of Fort Hare).
 26. Martin B, Pearson M, Kebejian L, Golden E. Nutrition and physiological function. *Nat Clin Pract Neurol.* 2007; 3: 374-82.
 27. Sachdeva M, Malik M, Purohit A, Jain L, Kaur K, Pradhan P et al. Association of iron deficiency and anemia with obesity among children: A systematic review and meta-analysis. *Obesity Reviews.* 2025 Jun; 26(6): e13892.
 28. Infante M, Padilla N, Alejandro R, Caprio M, Della-Morte D, Fabbri A et al. Diabetes-modifying antirheumatic drugs: the roles of dmards as glucose-lowering agents. *Medicina.* 2022 Apr 21; 58(5): 571.

